• Exchange: Tel Aviv
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Biocancell Ltd

+ Add to Watchlist

BICL:IT

230.00 ILs 10.80 4.49%

As of 10:24:31 ET on 07/31/2014.

Snapshot for Biocancell Ltd (BICL)

Open: 229.10 Day's Range: 228.20 - 231.90 Volume: 34,824
Previous Close: 240.80 52wk Range: 226.10 - 663.55 1-Yr Rtn: -64.36%

Stock Chart for BICL

No chart data available.
  • BICL:IT 229.40
  • 1D
  • 1M
  • 1Y
240.80
Interactive BICL Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for BICL

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. TA-100 -
Earnings Per Share (ttm) -1.4769
Est. EPS -
Est. PEG Ratio -
Market Cap (M ILS) 44.42
Shares Outstanding (M) 19.31
30 Day Average Volume 20,485
Price/Book (mrq) 4.1802
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/04/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for BICL

  • Revenue
  • Net Income (M/ILS)
  • Profit Margin (%)

Company Profile & Key Executives for BICL

BioCancell Ltd. is a biopharmaceutical company that develops targeted cancer therapy treatments for numerous types of cancer. The treatment is based on utilizing a target gene, such as the H19 gene, an oncofetal gene expressed at high levels in over 40 types of human cancer tissues, while existing at a nearly undetectable level in the surrounding normal tissues.

Aharon SchwartzChairmanJonathan BurginChief Executive Officer
Avraham HochbergChief Scientist/Co-FounderMonique Ben-AmVP:Clinical Development
More Company Profile & Key Executives for BICL

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil